1. No more disparities among regions in Italy: recent approval of genomic test reimbursability for early breast cancer patients in the country

   • Sara Bravaccini
   • Massimiliano Mazza
   • Roberta Maltoni

   Editorial 13 June 2023 Pages: 1 - 3

2. Identifying miRNA biomarkers for breast cancer and ovarian cancer: a text mining perspective

   • Xin Li
   • Andrea Dai
   • Jie Wang

   Review 17 June 2023 Pages: 5 - 14

   

3. Advances of neuroimaging in chemotherapy related cognitive impairment (CRCI) of patients with breast cancer

   • Senbang Yao
   • Qianqian Zhang
   • Huaidong Cheng

   Review 17 June 2023 Pages: 15 - 26

   

4. Heterogeneous circulating tumor cells correlate with responses to neoadjuvant chemotherapy and prognosis in patients with locally advanced breast cancer

   • Ge Ma
   • Jingyi Wang
   • Shui Wang

   Preclinical study 13 June 2023 Pages: 27 - 41

   

5. Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells

   • Taronish D. Dubash
   • Aditya Bardia
   • Shyamala Maheswaran

   Preclinical study Open access 15 June 2023 Pages: 43 - 56

   

6. Conventional specimen radiography in breast-conserving therapy: a useful tool for intraoperative margin assessment after neoadjuvant therapy?

   • Benedikt Schäfgen
   • Annabelle Haller
   • Michael Golatta

   Clinical trial Open access 11 June 2023 Pages: 57 - 66

   

7. Radiofrequency localization of nonpalpable breast cancer in a multicentre prospective cohort study: feasibility, clinical acceptability, and safety

   • Anke Christenhusz
   • Bianca M. den Dekker
   • Anneriet E. Dassen

   Clinical trial Open access 15 June 2023 Pages: 67 - 75

   

8. Impact of non-adherence to endocrine therapy on recurrence risk in older women with stage I breast cancer after breast-conserving surgery

   • Danielle Rodin
   • Rinku Sutradhar
   • Eileen Rakovitch

   Epidemiology 16 June 2023 Pages: 77 - 87

   

9. Survival benefits associated with being adherent and having longer persistence to adjuvant hormone therapy across up to five years among U.S. Medicare population with breast cancer

   • Dandan Zheng
   • Joseph Thomas III

   Epidemiology 16 June 2023 Pages: 89 - 104

10. Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 & 6 inhibitors in patients with HR+, HER2− MBC in the real world

    • Megan Kruse
    • Emily Nash Smyth
    • Kevin Kalinsky

    Epidemiology 13 June 2023 Pages: 105 - 115

    

11. Development of cardiometabolic risk factors following endocrine therapy in women with breast cancer

    • Eileen Rillamas-Sun
    • Marilyn L. Kwan
    • Heather Greenlee

    Epidemiology 16 June 2023 Pages: 117 - 126

12. Surviving the COVID-19 pandemic: navigating the recovery of breast imaging services in a safety-net hospital

    • Jessica H. Porembka
    • Stephen J. Seiler
    • Basak E. Dogan

    Epidemiology 18 June 2023 Pages: 127 - 138

    

13. Validating the PROMIS cognitive function short form in cancer survivors

    • Ashley M. Henneghan
    • Kathleen Van Dyk
    • Patricia A. Ganz

    Original Laboratory Investigation 17 June 2023 Pages: 139 - 145

14. Is there any association between declined creatinine clearence and higher endoxifen levels in older patients with non-metastatic breast cancer?

    • Kadri Altundag

    Letter to the Editor 17 June 2023 Pages: 147 - 147

15. It is the impact of racism, not race, that causes breast cancer inequities

    • Francois G. Rollin
    • Shub S. Agrawal
    • Mackenzie L. W. Garcia

    Letter to the Editor 19 June 2023 Pages: 149 - 150